Weight-loss and diabetes medications may lower cancer risk
Image credit: sweetlifediabetes via Unsplash
A recent study published in the journal JAMA Network Open has found that popular diabetes and weight-loss management medications such as Ozempic and Wegovy are linked to a reduced risk of certain cancers in people with type 2 diabetes. The study highlights how these drugs, beyond their primary purposes, offer protective benefits against cancer development. This discovery opens new avenues for understanding how metabolic health influences cancer risk and suggests that these medications could play a dual role in managing both metabolic disorders and reducing cancer incidence.
Source
Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305
Additional Reading
https://www.cnn.com/2024/07/05/health/glp-1-weight-loss-lower-cancer-risk/index.html